Purchase this article with an account.
M. Fukushima, T. Kawaji, N. Awai, A. Takano, Y. Inomata, A. Hirata, H. Tanihara; Trans–Tenon's Retrobulbar Triamcinolone Infusion for Macular Edema Associated With Branch Retinal Vein Occlusion Remaining After Vitrectomy . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4041.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To evaluate the safety and effectiveness of trans–Tenon’s retrobulbar triamcinolone infusion for macular edema associated with branch retinal vein occlusion (BRVO) remaining even after vitrectomy Methods: Twenty eyes of 20 patients with BRVO, characterized by macular edema remaining more than 3 months even after vitrectomy, were enrolled in this study. Trans–Tenon’s retrobulbar infusion of 40mg triamcinolone was performed. Visual acuity, retinal thickness measured by optical coherence tomography (OCT), fluorescein angiography and intraocular pressure (IOP) were evaluated. Results: The mean duration (± standard deviation) between surgeries and triamcinolone infusion was 7.7 ± 4.5 months (range, 3–21 months). The mean foveal thickness was 499.4 ± 209.1 µm, 281.8 ± 110.1µm, and 196.9 ± 92.1 µm, respectively, preoperatively, at 2 weeks, and at 6 months follow–up. Statistical analysis showed significant differences between preoperative and postoperative measurements (P<.0001, at 2 weeks and 6 months, paired t–test). Visual acuity improved significantly from preoperative 0.74 ± 0.26 logMAR (range, 1.1 to 0.3) to 0.46 ± 0.31 logMAR (range, 1.0 to 0) (P<.0001) at 6 months follow–up. Improvement of visual acuity by at least 0.20 logMAR was seen in 14 (70%) of the 20 eyes. In all of the treated eyes, vascular leakiness shown by the fluorescein angiograms was improved at 1 month follow–up. Intraocular pressure (IOP) elevation of 22 mmHg or higher was found in 7 (35%) of the 20 eyes, and IOP was controlled with anti–glaucoma medications in all cases. Conclusions:Our studies showed that trans–Tenon’s retrobulbar triamcinolone infusion is safe and effective for macular edema associated with BRVO remaining after vitrectomy.
This PDF is available to Subscribers Only